Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinbei Rukang Pian is a Chinese patent medicine (CPM) developed and manufactured by Guangxi Zhuang Autonomous Region Huahong Pharmaceutical Co., Ltd. It is specifically indicated for the treatment of breast hyperplasia (also known as fibrocystic breast changes or mastopathy). The formulation is based on Traditional Chinese Medicine (TCM) principles, designed to clear heat, resolve phlegm, and dissipate nodules. Its primary therapeutic goals are to alleviate breast pain (mastalgia) and reduce the size of glandular lumps associated with hyperplastic mammary tissue. The product contains a blend of herbal ingredients, including *Fritillaria thunbergii*, *Taraxacum*, and *Prunella vulgaris*, which are believed to exert anti-inflammatory and regulatory effects on the breast tissue environment. It is administered orally in tablet form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinbei Rukang Pian.